Laboratory for Advanced Medicine

Laboratory for Advanced Medicine (LAM), now operating as Helio Health, is a commercial-stage biotechnology company specializing in the early detection of cancer through DNA methylation-based liquid biopsy technology. The company's platform identifies cancer-specific epigenetic signatures in cell-free DNA (cfDNA) to provide non-invasive diagnostic tests. Its lead product, HelioLiver, is a multi-analyte blood test designed for the early detection of hepatocellular carcinoma in high-risk populations. Additionally, the company offers the IvyGene test, which provides multi-cancer detection capabilities across several common cancer types. LAM maintains a global presence with operations in the United States and China, leveraging large-scale clinical trials to validate its diagnostic algorithms. By focusing on high-incidence cancers, the company aims to significantly improve patient survival rates through earlier intervention and more effective monitoring.